

Financial Tear Sheet

Corporate Profile

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Accuray does not assume a duty to update information on this website, except through the normal quarterly financial press releases and regulatory filings.

Stock Performance

ARAY (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$5.05
Change (%)	▼ 0.1 (1.94%)
Volume	512,490
52 Week Low	\$3.60
Market Cap	\$430,731,029
Rolling EPS	-0.29
PE Ratio	N/A
Shares Outstanding	85,293,273

Data as of Feb 22, 2018 4:00 p.m. ET



Press Releases

Feb 15, 2018 - 4:03 p.m.

Accuray to Present at the 2018 RBC Capital Markets
Global Healthcare Conference on February 22, 2018

Feb 5, 2018 - 7:00 a.m.





Accuray Retires February 2018 Convertible Notes

Jan 29, 2018 - 7:34 a.m.

Study Shows CyberKnife® System Provides
Long-Lasting Pain Relief for Trigeminal Neuralgia
Patients

Supporting Materials

SEC Filings

Filing Date	Form	
Feb 15, 2018	SC 13G	
Feb 14, 2018	SC 13G/A	
Feb 14, 2018	SC 13G/A	
Feb 13, 2018	SC 13G/A	

Corporate Governance

Joshua H. Levine	President and Chief Executive Officer
LIONEL HADJADJEBBA	CORPORATE SENIOR VICE PRESIDENT, CHIEF COMMERCIAL OFFICER
Kevin Waters	Senior Vice President, Chief Financial Officer
Darl S. Moreland	Senior Vice President, Regulatory, Quality and Compliance
Alaleh Nouri	Senior Vice President, General Counsel and Corporate Secretary
Andy Kirkpatrick	Senior Vice President, Global Operations and Corporate Development
Robert Hill	Senior Vice President, Corporate Development

Data provided by Nasdaq. Minimum 15 minutes delayed.